[A comparative study of the myeloprotective effect of dicarbamine and leucostim in experimental post-radiation bone marrow syndrome].

We studied the effect of dicarbamine and leucostim on myelopoiesis in experimental post-radiation bone marrow syndrome. Dicarbamine in different modes of administration and doses provided a high level of protection of proliferating hematopoietic precursors in the early period after radiation, which was reflected in a statistically significant decrease in the depth and duration of post-radiation deficit of cells, such as of granulocytes, lymphocytes, megakaryocytes and erythroid cells. The greatest effect of the drug appeared at a dose of 4 mg/kg (prophylactic administration) and a dose of 15 mg/kg (curative double dose). In the bone marrow of experimental animals leucostim prevented development of post-radiation deficit of granulocytes and lymphocytes to a lesser extent, than dicarbamine, and it was effective for erythroid cells and megakaryocytes.

[Comparative study of the hemato-protective effect of Dicarbamine and Leykostime in experimental radiation damage to the blood system].

There was studied the influence Dicarbamine and Leykostime on peripheral blood leukocyte composition of rabbits in experimental radiogenic damage to the blood system. Dicarbamine significantly insured the safety of circulating red blood cells, prevented the development of severe postradiation thrombocytopenia, reduced postradiation leukocytopenia, and accelerated the recovery of peripheral blood leukocytes to the initial level by segmented neutrophils and lymphocytes. Leukostime ensured the safety of peripheral blood leukocytes however was less effective than Dicarbamine to prevent postradiation deficit of circulating red blood cells and thrombocytes.

[Modification of hematosupressive action of ionizing radiation by dicarbamine].

There was studied the effect of different doses of Dicarbamine by means of oral medical-prophylactic and medical administration on the peripheral blood of rabbits in conditions of experimental radiation damage to the blood system. The drug provided the safety of circulating red blood cells at rather high level, prevented the development of severe post-radiation thrombocytopenia, reduced post-radiation leukocytopenia, accelerated processes of recovery of peripheral blood leukocytes to the initial level by segmented neutrophils and lymphocytes.

[Hematoprotective effectiveness of dicarbamin in experimental post-radiation bone marrow syndrome].

The effect of dicarbamin on cellular composition of rabbits' venous blood in experimental post-radiation bone marrow syndrome was studied. The dicarbamin use has allowed to reduce depth and to shorten the duration of post-radiation leukocytopenia.

[Effect of dicarbamine on medullary hemopoiesis in experimental post-irradiation bone-marrow syndrome].

The effect of dicarbamine on hemopoiesis in experimental post-irradiation bone-marrow syndrome was studied. The myeloprotective activity of the drug was established. It manifested in the protection of hematopoietic progenitor cells and stimulation of cell proliferation and differentiation in the bone marrow.